Mitsubishi UFJ Asset Management Co. Ltd. Acquires 8,172 Shares of Insulet Corporation $PODD

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Insulet Corporation (NASDAQ:PODD) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 147,449 shares of the medical instruments supplier’s stock after purchasing an additional 8,172 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Insulet were worth $41,716,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Whittier Trust Co. of Nevada Inc. raised its position in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 43 shares during the period. Quent Capital LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at approximately $49,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at approximately $49,000. Osterweis Capital Management Inc. acquired a new stake in shares of Insulet in the 2nd quarter valued at approximately $51,000. Finally, Zions Bancorporation National Association UT raised its position in shares of Insulet by 57.3% in the 3rd quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 63 shares during the period.

Insulet Stock Performance

Shares of PODD stock opened at $154.16 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.15 and a current ratio of 2.49. The company has a market capitalization of $10.68 billion, a P/E ratio of 35.85, a price-to-earnings-growth ratio of 0.92 and a beta of 1.20. The company’s 50 day moving average price is $211.22 and its two-hundred day moving average price is $263.85. Insulet Corporation has a 52 week low of $148.30 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period last year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PODD. Wall Street Zen upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Piper Sandler cut their price target on shares of Insulet from $360.00 to $210.00 in a research report on Wednesday. Raymond James Financial cut their price target on shares of Insulet from $355.00 to $263.00 in a research report on Thursday. Robert W. Baird cut their price target on shares of Insulet from $360.00 to $248.00 in a research report on Thursday. Finally, Wells Fargo & Company cut their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday. Eighteen equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.09.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s Q1 results beat expectations, with revenue of $761.7 million and EPS of $1.42, and management raised full-year revenue growth guidance to 21%–23%, reinforcing momentum in its Omnipod diabetes platform.
• Positive Sentiment: The company highlighted strong international Omnipod growth and continued expansion of Omnipod 5 into new markets, which suggests the core business remains healthy. Article Title
• Neutral Sentiment: Recent earnings-call coverage and transcript coverage continued to emphasize improved profitability and upbeat management commentary following the Q1 report. Article Title
• Negative Sentiment: Multiple Wall Street firms cut price targets sharply after the earnings report, including Piper Sandler, JPMorgan, Citigroup, Wells Fargo, Stifel, Raymond James, Canaccord Genuity, Leerink, and others, which likely pressured the shares.
• Negative Sentiment: The stock is also trading well below several recent analyst targets, and the cluster of downgrades/target reductions may be signaling concerns about valuation or the pace of future upside despite the earnings beat.

Insider Buying and Selling

In related news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were purchased at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.36% of the company’s stock.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.